New pill targets Hard-to-Treat cancers with a specific gene mutation

NCT ID NCT06040541

Recruiting now Disease control Sponsor: Revolution Medicines, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral drug, RMC-6236. The main goals are to check safety, find the right dose, and see how the body handles the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RMC-9805 (oral tablet) and RMC-6236 (oral tablet)

What this could lead to

If successful, this could lead to a new targeted treatment option for people with hard-to-treat cancers that have a KRAS G12D mutation.

What could go wrong

This is an early-phase trial (Phase 1/1b) focused on safety and dosing, so it is not yet known if the drug will shrink tumors or improve survival. Side effects are possible, and the drug may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal neoplasm digestive system neoplasm lung neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS COLORECTAL CANCER (CRC) NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States
Lee Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
NYU Langone
RECRUITING

New York, New York, 10016, United States
START
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at Mary Crowley
RECRUITING

Dallas, Texas, 75230, United States
Smilow Cancer Hospital (Yale University)
RECRUITING

New Haven, Connecticut, 06511, United States
The Christ Hospital
RECRUITING

Cincinnati, Ohio, 45219, United States
University of California, Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States
University of Texas, MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States